ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada

CANNANNEW REPORT

Launch of Zylem™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that the company has launched a new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential. ZYUS refines its cannabinoid extracts in an industry leading, pharmaceutical-grade extraction facility using raw material exclusively from licensed producers regulated by Health Canada. ZYUS’ ethanol-based technology is used to achieve superior extraction efficiency while ensuring a high product quality and long shelf life. ZYUS is committed to the highest quality, with all products undergoing rigorous testing from production to distribution, to ensure consistent and standardized formulations that patients and healthcare practitioners can depend on. “At ZYUS, we are committed to providing patients with compassionate care high-quality formulations backed by our team’s decades-long leadership in medical cannabinoids,” said ZYUS CEO Brent Zettl. “With millions of Canadians suffering, we are proud to offer patients another new cannabinoid formulation to help manage their condition and associated symptoms.” Further expanding the existing ZYUS medical product offerings of cannabinoid extracts and cannabinoid topical formulations, this new THC-dominant extract formulation (Zylem™ 20:1), is available for direct sales and distribution to registered medical patients across Canada. Prospective patients or healthcare practitioners seeking more information about ZYUS, or its products can visit ZYUS.ca or speak to a member of the ZYUS patient care team at 1-833-713-CARE (2273). About ZYUS Life Sciences Inc. ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical…

Excerpt only …
READ MORE BELOW
Source : ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.